Assessment of Symptom-Free Survival and Health-Related Quality of Life After Coronary Artery Bypass Grafting for Chronic Total Coronary Occlusion
Journal of MedVerse Research & Practice · 31.10.2026 · 18
DOI: 10.65188/nurexus.1108 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of MedVerse Research & Practice, online erschienen am 31.10.2026. Verfasst von Ramanujam J und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Chronic total occlusion (CTO) of a major epicardial coronary artery is a manifestation of advanced coronary artery disease and is frequently associated with persistent myocardial ischemia, reduced functional capacity, and impaired quality of life. Although coronary artery bypass grafting (CABG) is an established revascularization strategy, evidence regarding long-term symptom-free survival and patient-reported quality-of-life outcomes among patients with CTO remains limited.
Objectives
To assess symptom-free survival among patients with CTO who underwent elective CABG and were followed up for a minimum of 24 months, and to evaluate their postoperative quality of life.
Methods
This retrospective cohort study included adult patients who underwent elective CABG for documented CTO at a tertiary cardiac center between January 2020 and December 2025, with a minimum follow-up period of 24 months. Demographic characteristics, clinical profiles, comorbidities, operative variables, and preoperative risk scores, including EuroSCORE II and SYNTAX II, were obtained from institutional medical records. Symptom-free survival was assessed through follow-up records and structured telephonic interviews. Postoperative quality of life and functional capacity were evaluated using the Seattle Angina Questionnaire and Duke Activity Status Index (DASI), respectively. Kaplan-Meier survival analysis and appropriate statistical tests were performed, with a p-value of less than 0.05 considered statistically significant.
Results
A total of 177 patients with 222 CTO lesions were included in the analysis, with most patients having single- vessel involvement. At three years of follow-up, nearly half of the patients remained free from recurrent angina. Chronic obstructive pulmonary disease was significantly associated with reduced symptom-free survival (p < 0.05), whereas diabetes mellitus, hypertension, left ventricular dysfunction, and preoperative risk scores did not demonstrate significant associations. DASI scores were significantly influenced by diabetes mellitus and hypertension and showed an inverse correlation with predicted mortality scores.
Conclusion
Elective CABG in carefully selected patients with CTO is associated with meaningful mid-term symptom-free survival and satisfactory postoperative quality-of-life outcomes. Chronic obstructive pulmonary disease may adversely influence postoperative symptom relief, while conventional cardiovascular risk factors demonstrated limited association with symptom-free survival. These findings highlight the importance of individualized risk assessment and multidisciplinary management when considering surgical revascularization. Keywords: Chronic total occlusion Coronary artery bypass grafting Symptom-free survival Quality of life Duke Activity Status Index SYNTAX score EuroSCORE II
Zitieren
APA
J, R., & S, V. (2026). Assessment of Symptom-Free Survival and Health-Related Quality of Life After Coronary Artery Bypass Grafting for Chronic Total Coronary Occlusion. Journal of MedVerse Research & Practice, 18. https://doi.org/10.65188/nurexus.1108
Vancouver
J R, S V. Assessment of Symptom-Free Survival and Health-Related Quality of Life After Coronary Artery Bypass Grafting for Chronic Total Coronary Occlusion. Journal of MedVerse Research & Practice. 2026:18. doi:10.65188/nurexus.1108
BibTeX
@article{J2026,
author = {J, Ramanujam and S, Vasanthi},
title = {Assessment of Symptom-Free Survival and Health-Related Quality of Life After Coronary Artery Bypass Grafting for Chronic Total Coronary Occlusion},
journal = {Journal of MedVerse Research & Practice},
year = {2026},
pages = {18},
doi = {10.65188/nurexus.1108}
}
EUVIMED